Do I really need a long-term disability policy?The chances of needing long-term disability insurance are higher than you might think and can be worth the expense
In this issue
Most robotic RPs performed at low-volume hospitals August 01, 2017By Badar M. Mian MDIn a recent study, increasing hospital volume was significantly associated with improved perioperative outcomes.
Urology-specific quality measures are coming August 01, 2017By Bob GattyTwo electronic Clinical Quality Measures will help urologists report on prostate and bladder cancer care.
QoL better with bladder Ca immunotherapy vs. chemoPatients treated with pembrolizumab (Keytruda) as second-line therapy for advanced urothelial carcinoma following platinum-based chemotherapy maintain better health-related quality of life than their counterparts receiving chemotherapy, according to results from the phase III KEYNOTE-045 trial presented at the American Society of Clinical Oncology annual meeting in Chicago.
How will immunotherapy change the future of bladder Ca care? July 21, 2017By Karen NashUrology Times reached out to three urologists (selected randomly and asked them each the following question: How will immunotherapy change the future of bladder Ca care? Side effects of modern PCa treatments compared August 01, 2017By Wayne KuznarDespite technological advances in treatment for localized prostate cancer, men continue to experience clinically meaningful side effects that affect quality of life, according to an examination of data from a prospective population-based cohort study. Metformin may improve advanced prostate Ca outcomesMetformin may act synergistically with androgen deprivation therapy to improve outcomes for men with advanced prostate cancer, according to findings of an observational study presented at the AUA annual meeting in Boston. Proposed MIPS rule modifies 2018 requirementsThe proposed rule for MACRA and the Merit-based Incentive Payment System program was released June 21, 2017-- As expected, the program requiring the implementation of the new MIPS scoring system and incentives to move to alternative payment models will continue. Quality initiatives: How to participate—and benefit July 31, 2017By Lisette HiltonChanges in health care have made quality improvement (QI) program participation more than a good idea. Today, QI activities are part of the alphabet soup of regulations impacting provider pay. A snapshot of recent urology QI programs July 31, 2017By Lisette HiltonQuality improvement programs address all aspects of care and care delivery. Here are a few programs that impact urology, all of which were presented at the AUA annual meeting in Boston. How prostate cancer genetics will change front-line care August 01, 2017By Stacy Loeb MD MScIn this interview, Leonard G. Gomella, MD, provides an update on prostate cancer genetics, discusses the recent Prostate Cancer International Consensus Conference, and outlines why urologists should conduct more extensive family histories of their prostate cancer patients. Incontinence after RP or RT: Consider preventive measures first August 10, 2017By Richard R. KerrIn this interview, SUNA President Gwendolyn Hooper, PhD, APRN, discusses practical tips for prevention and management of incontinence in men treated for localized prostate cancer. 5-ARI may have adverse metabolic effects August 14, 2017By Andrew BowserAuthors of a recent study say that long-term therapy with a 5-alpha-reductase inhibitor was associated with increased glucose, increased glycated hemoglobin, and altered lipid profiles.
Men must be entitled to PCa screening, treatment choiceThe following letter was sent to Urology Times in response to a previously published letter to the editor, "Dear USPSTF: Don't discount value of PSA in men 70+." Smoking linked to tumor heterogeneity for bladder CaResearchers from Wake Forest Baptist Comprehensive Cancer Center have made novel discoveries about the genomic signatures of cancers—including bladder cancer—in smokers and African-American patients.
Genomic research may explain resistance to immunotherapyNew research characterizing the molecular mechanisms regulating immune cell infiltration into the luminal subtype of muscle-invasive bladder cancer may explain resistance to treatment with immune checkpoint blockade and suggest a target for improving therapeutic response.